Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Vasily Shuvaev, MD, Mikhail Fominykh, MD, Vera Udaleva, MD, Irina I Zotova, MD, Regina Golovchenko, MD PhD, Dzhariyat Shikhbabaeva, MD, Irina Martynkevich, DSc, Lyudmila Martynenko, Marina Ivanova, MD PhD, Natalya Tsybakova, PhD, Ekaterina Motyko, PhD, Lyubov Polushkina, MD, Nadezhda Potikhonova, MD PhD, Sophya Tyranova, MD PhD, Marina Zenina, MD PhD, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5441.

https://doi.org/10.1182/blood.V128.22.5441.5441

Published: 2016

Journal Articles

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Blood (2016) 128 (22): 5442.

https://doi.org/10.1182/blood.V128.22.5442.5442

Published: 2016

Journal Articles

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Heinz Gisslinger, MD, Christoph Klade, Kudrat Abdulkadyrov, MD, Slawomira Kyrcz-Krzemien, MD PhD, Elena Karyagina, MD, Anait L. Melikyan, MD PhD, Krzysztof Warzocha, Barbara Grohmann-Izay, MD, Juri Hodisch, MD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, Petro E. Petrides, MD PhD, Jiri Schwarz, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 476.

https://doi.org/10.1182/blood.V128.22.476.476

Published: 2016

Journal Articles

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Dzhariyat Shikhbabaeva, MD, Vasily Shuvaev, MD, Regina Golovchenko, MD PhD, Vera Udaleva, MD, Mikhail Fominykh, MD, Irina I Zotova, MD, Lyubov Polushkina, MD, Irina Martynkevich, DSc, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5475.

https://doi.org/10.1182/blood.V128.22.5475.5475

Published: 2016

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, MD PhD, Andrey Zaritskey, MD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Mikhail Fominykh, MD, Ekaterina Ovsyannikova, MD, Natalia Lazorko, MD, Natalia Matyuhina, MS, Pavel Butylin, PhD, Elena Machyulaitene, MD, Evgenia Salamatova, MD, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 4051.

https://doi.org/10.1182/blood.V126.23.4051.4051

Published: 2015

Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD

Blood (2015) 126 (23): 5288.

https://doi.org/10.1182/blood.V126.23.5288.5288

Published: 2015

Journal Articles

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Vasily Shuvaev, MD, Kudrat Abdulkadyrov, MD PhD, Anna Turkina, Prof., MD, Irina Martynkevich, MD PhD, Ekaterina Chelysheva, MD PhD, Mikhail Fominykh, MD, Valentin Martchenko

Blood (2015) 126 (23): 3293.

https://doi.org/10.1182/blood.V126.23.3293.3293

Published: 2015

Journal Articles

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Blood (2015) 126 (23): 5150.

https://doi.org/10.1182/blood.V126.23.5150.5150

Published: 2015

Journal Articles

The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera

Dzhariyat Shikhbabaeva, Vasily Shuvaev, MD, Sergey Kapustin, PhD, Irina Martynkevich, MD PhD, Vera Udaleva, MD, Regina Golovchenko, MD, Tatyana Zamotina, Mikhail Fominykh, MD, Irina Zotova, Lyubov Polushkina, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 5180.

https://doi.org/10.1182/blood.V126.23.5180.5180

Published: 2015

Journal Articles

The Results of the Russian Registry of Primary Immune Thrombocytopenia (ITP) in Adults

Blood (2015) 126 (23): 4642.

https://doi.org/10.1182/blood.V126.23.4642.4642

Published: 2015

Journal Articles

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Marco Aurelio Salvino, MD PhD, Ong Tee Chuan, MD, Alaa Elhaddad, MD PhD, Kudrat Abdulkadyrov, MD PhD, Jake Shortt, MD, Hang Quach, MD, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Lee-Yung Shih, MD, Anna G. Turkina, MD PhD, Luis Meillon, MD, Yu Jin, MS, Sadhvi Khanna, MS, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 344.

https://doi.org/10.1182/blood.V126.23.344.344

Published: 2015

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

Journal Articles

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Blood (2014) 124 (21): 3148.

https://doi.org/10.1182/blood.V124.21.3148.3148

Published: 2014

Journal Articles

Genetic and Epigenetic Alterations of Ph-Negative Myeloproliferative Neoplasms

Lyubov Polushkina, Irina Martynkevich, PhD, Vasily Shuvaev, MD, Ekaterina Petrova, Lyudmila Martynenko, Natalya Cybakova, MD, Marina Ivanova, MD, Elizaveta Kleina, Elena Shabanova, Dzhariyat Shikhbabaeva, Tatyana Zamotina, Mikhail Fominykh, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5549.

https://doi.org/10.1182/blood.V124.21.5549.5549

Published: 2014

Journal Articles

Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience

Vasily Shuvaev, MD, Irina Martynkevich, PhD, Alla Abdulkadyrova, Vera Udaleva, MD, Tatyana Zamotina, Mikhail Fominykh, Regina Golovchenko, Irina Zotova, Dzhariyat Shikhbabaeva, Lyubov Polushkina, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5556.

https://doi.org/10.1182/blood.V124.21.5556.5556

Published: 2014

Journal Articles

Effect of Eculizumab on Physician-Reported Symptoms in the Russian Cohort of the Paroxysmal Nocturnal Hemoglobinuria (PNH) International Registry

Blood (2014) 124 (21): 5163.

https://doi.org/10.1182/blood.V124.21.5163.5163

Published: 2014

Journal Articles

Early Molecular Response in Chronic Myeloid Leukemia Patients Predicts Future Response Status

Irina Martynkevich, PhD, Vasily Shuvaev, MD, Ekaterina Petrova, Lyubov Polushkina, Lyudmila Martynenko, Marina Ivanova, MD, Natalya Cybakova, MD, Elizaveta Kleina, Elena Shabanova, Mikhail Fominykh, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5529.

https://doi.org/10.1182/blood.V124.21.5529.5529

Published: 2014

Journal Articles

Importance of DNMT3A Gene mutations detection in Prognostic Analyses of Patients with Acute Myeloid Leukemia

Ekaterina Petrova, Irina Martynkevich, PhD, Lyubov Polushkina, Lyudmila Martynenko, Marina Ivanova, MD, Natalya Cybakova, MD, Elena Shabanova, Ilya Zyuzgin, MD, Elena Karyagina, Sergey Gritsaev, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5321.

https://doi.org/10.1182/blood.V124.21.5321.5321

Published: 2014

Journal Articles

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Anna G. Turkina, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Vasiliy Shuvaev, Galina Gusarova, MD PhD, Anastasia Bykova, MD, Olga V. Lazareva, PhD, Oleg Shukhov, MD, Adham Abdullaev, MD PhD, Irina Martynkevich, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5518.

https://doi.org/10.1182/blood.V124.21.5518.5518

Published: 2014

NARROW

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera

The Results of the Russian Registry of Primary Immune Thrombocytopenia (ITP) in Adults

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Genetic and Epigenetic Alterations of Ph-Negative Myeloproliferative Neoplasms

Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience

Effect of Eculizumab on Physician-Reported Symptoms in the Russian Cohort of the Paroxysmal Nocturnal Hemoglobinuria (PNH) International Registry

Early Molecular Response in Chronic Myeloid Leukemia Patients Predicts Future Response Status

Importance of DNMT3A Gene mutations detection in Prognostic Analyses of Patients with Acute Myeloid Leukemia

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only